<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: clinical response</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Individual efficacy of chemotherapies</title>
   	 <description>The function of the mitochondria – also defined as &quot;power plants&quot; within the cells – is essential as to whether, and how, some chemotherapeutic agents take effect in tissue. Scientists at the Helmholtz Zentrum München have thus discovered a significant cell characteristic that could possibly predict the success of therapy. Their results will soon be published in the trade magazine The Journal of Pathology.</description>
     <link>http://medicalxpress.com/news/2013-05-individual-efficacy-chemotherapies.html</link>
	 <category>Cancer</category>
	 <pubDate>Fri, 10 May 2013 08:38:56 EST</pubDate>
	 <guid isPermaLink="false">news287393928</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/individualef.jpg" width="90" height="90" />
</item>
<item>
     <title>Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer</title>
   	 <description>A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.</description>
     <link>http://medicalxpress.com/news/2013-05-everolimus-trastuzumab-resistance-her-positive.html</link>
	 <category>Cancer</category>
	 <pubDate>Thu, 02 May 2013 10:35:22 EST</pubDate>
	 <guid isPermaLink="false">news286709710</guid>
	 
</item>
<item>
     <title>Common gene variants explain 42% of antidepressant response</title>
   	 <description>Antidepressants are commonly prescribed for the treatment of depression, but many individuals do not experience symptom relief from treatment. The National Institute of Mental Health's STAR*D study, the largest and longest study ever conducted to evaluate depression treatment, found that only approximately one-third of patients responded within their initial medication trial and approximately one-third of patients did not have an adequate clinical response after being treated with several different medications. Thus, identifying predictors of antidepressant response could help to guide the treatment of this disorder.</description>
     <link>http://medicalxpress.com/news/2013-03-common-gene-variants-antidepressant-response.html</link>
	 <category>Psychology &amp; Psychiatry</category>
	 <pubDate>Thu, 28 Mar 2013 08:38:59 EST</pubDate>
	 <guid isPermaLink="false">news283678728</guid>
	 
</item>
<item>
     <title>Newer, shorter-course antibiotic shows similar effectiveness for treating skin infection</title>
   	 <description>Treatment with a newer antibiotic, tedizolid phosphate, once daily for 6 days was statistically noninferior (no worse than) in efficacy to the antibiotic linezolid twice daily for 10 days for both early (at day 2 to 3) and sustained (at day 11) clinical responses in patients with acute bacterial skin and skin structure infections, according to a study appearing in the February 13 issue of JAMA.</description>
     <link>http://medicalxpress.com/news/2013-02-shorter-course-antibiotic-similar-effectiveness-skin.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Tue, 12 Feb 2013 16:30:02 EST</pubDate>
	 <guid isPermaLink="false">news279906626</guid>
	 
</item>
<item>
     <title>Fulyzaq approved for ART-related diarrhea in HIV/AIDS</title>
   	 <description>(HealthDay)—The first medication to treat diarrhea in people with HIV/AIDS who take antiretroviral drugs has been approved by the U.S. Food and Drug Administration.</description>
     <link>http://medicalxpress.com/news/2013-01-fulyzaq-art-related-diarrhea-hivaids.html</link>
	 <category>Medications</category>
	 <pubDate>Thu, 03 Jan 2013 10:32:00 EST</pubDate>
	 <guid isPermaLink="false">news276431502</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/fulyzaqappro.jpg" width="90" height="90" />
</item>
<item>
     <title>Adalimumab relieves hidradenitis suppurativa</title>
   	 <description>(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly adalimumab is associated with improvements in pain and inflammation, according to a study published online Dec. 17 in the Annals of Internal Medicine.</description>
     <link>http://medicalxpress.com/news/2012-12-adalimumab-relieves-hidradenitis-suppurativa.html</link>
	 <category>Inflammatory disorders</category>
	 <pubDate>Tue, 18 Dec 2012 18:07:14 EST</pubDate>
	 <guid isPermaLink="false">news275076428</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2012/adalimumabre.jpg" width="90" height="90" />
</item>
<item>
     <title>Study finds potential new drug therapy for Crohn's disease</title>
   	 <description>Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the October 18, 2012 issue of the New England Journal of Medicine (NEJM).</description>
     <link>http://medicalxpress.com/news/2012-10-potential-drug-therapy-crohn-disease.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Wed, 17 Oct 2012 17:00:07 EST</pubDate>
	 <guid isPermaLink="false">news269705442</guid>
	 
</item>
<item>
     <title>Azathioprine may benefit pediatric atopic dermatitis</title>
   	 <description>(HealthDay) -- For pediatric patients with refractory atopic dermatitis (AD), oral azathioprine is associated with clinical improvement, and measurement of thiopurine methyltransferase (TPMT) activity seems useful for monitoring treatment, according to a study published online Aug. 13 in the Journal of the American Academy of Dermatology.</description>
     <link>http://medicalxpress.com/news/2012-08-azathioprine-benefit-pediatric-atopic-dermatitis.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Tue, 21 Aug 2012 15:00:01 EST</pubDate>
	 <guid isPermaLink="false">news264774183</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2012/azathioprine.jpg" width="90" height="90" />
</item>
<item>
     <title>Study identifies potential new class of drug for treating ulcerative colitis</title>
   	 <description>An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM).</description>
     <link>http://medicalxpress.com/news/2012-08-potential-class-drug-ulcerative-colitis.html</link>
	 <category>Diseases, Conditions, Syndromes</category>
	 <pubDate>Wed, 15 Aug 2012 17:00:16 EST</pubDate>
	 <guid isPermaLink="false">news264262927</guid>
	 
</item>
<item>
     <title>Researchers find potential solution to melanoma's resistance to vemurafenib</title>
   	 <description>Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.</description>
     <link>http://medicalxpress.com/news/2012-02-potential-solution-melanoma-resistance-vemurafenib.html</link>
	 <category>Cancer</category>
	 <pubDate>Tue, 28 Feb 2012 16:33:32 EST</pubDate>
	 <guid isPermaLink="false">news249669204</guid>
	 
</item>
<item>
     <title>Increasing dosage of clopidogrel for patients with genetic variation improves response to medication</title>
   	 <description>Among patients with stable cardiovascular disease who have a genetic variation that diminishes the response to the antiplatelet drug clopidogrel, tripling the standard daily dosage of this medication resulted in improved platelet reactivity, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American Heart Association Scientific Sessions.</description>
     <link>http://medicalxpress.com/news/2011-11-dosage-clopidogrel-patients-genetic-variation.html</link>
	 <category>Cardiology</category>
	 <pubDate>Wed, 16 Nov 2011 09:15:01 EST</pubDate>
	 <guid isPermaLink="false">news240657289</guid>
	 
</item>
<item>
     <title>Impact of clinical and echocardiographic response to cardiac resynchronization therapy</title>
   	 <description>The echocardiographic response (reduction of left ventricular end-systolic volume) evaluated at 6 months follow-up, demonstrated to be a better predictor of long-term mortality than improvement in clinical status in a large population of CRT patients. Therefore, assessment of occurrence of left ventricular reverse remodeling at mid-term follow-up may be an adequate surrogate end point in heart failure patients treated with CRT.</description>
     <link>http://medicalxpress.com/news/2011-08-impact-clinical-echocardiographic-response-cardiac.html</link>
	 <category>Cardiology</category>
	 <pubDate>Mon, 29 Aug 2011 11:26:16 EST</pubDate>
	 <guid isPermaLink="false">news233835952</guid>
	 
</item>


</channel>
</rss>
